Caverly Rae Jessica M, Frame Steven R, Kennedy Gerald L, Butenhoff John L, Chang Shu-Ching
DuPont Haskell Global Centers, Newark, DE 19714, USA.
Consultant to DuPont Company, Wilmington, DE 19805, USA.
Toxicol Rep. 2014 May 2;1:85-91. doi: 10.1016/j.toxrep.2014.04.005. eCollection 2014.
Two chronic dietary studies, conducted years apart, with ammonium perfluorooctanoate (APFO) in Sprague Dawley rats have been previously reported. Although both included male 300 ppm dietary dose groups, only the later study, conducted in 1990-1992 by Biegel et al., reported an increase in proliferative lesions (hyperplasia and adenoma) of the acinar pancreas. An assessment of the significance of the differences between both studies requires careful consideration of: the diagnostic criteria for proliferative acinar cell lesions of the rat pancreas (for example, the diagnosis of pancreatic acinar cell hyperplasia adenoma is based on the two-dimensional size of the lesion rather than distinct morphological differences); the basis for those criteria in light of their relevance to biological behavior; and the potential diagnostic variability between individual pathologists for difficult-to-classify lesions. A pathology peer review of male exocrine pancreatic tissues from the earlier study, conducted in 1981-1983 by Butenhoff et al., was undertaken. This review identified an increase in acinar cell hyperplasia but not adenoma or carcinoma in the earlier study. Both studies observed a proliferative response in the acinar pancreas which was more pronounced in the study by Biegel et al. Definitive reasons for the greater incidence of proliferative lesions in the later study were not identified, but some possible explanations are presented herein. The relevance of this finding to human risk assessment, in the face of differences in the biological behavior of human and rat pancreatic proliferative lesions and the proposed mechanism of formation of these lesions, are questionable.
此前曾报道过两项在不同年份对斯普拉格-道利大鼠进行的全氟辛酸铵(APFO)慢性饮食研究。尽管两项研究都设置了雄性大鼠300 ppm的饮食剂量组,但只有后来由比格尔等人在1990 - 1992年进行的研究报告了腺泡胰腺增生性病变(增生和腺瘤)有所增加。要评估两项研究之间差异的显著性,需要仔细考虑以下几点:大鼠胰腺腺泡细胞增生性病变的诊断标准(例如,胰腺腺泡细胞增生/腺瘤的诊断基于病变的二维大小,而非明显的形态学差异);鉴于这些标准与生物学行为的相关性,其依据是什么;以及对于难以分类的病变,个体病理学家之间潜在的诊断变异性。对布滕霍夫等人在1981 - 1983年进行的早期研究中的雄性外分泌胰腺组织进行了病理学同行评审。该评审发现早期研究中腺泡细胞增生有所增加,但未发现腺瘤或癌。两项研究都观察到腺泡胰腺有增殖反应,且在比格尔等人的研究中更为明显。后期研究中增生性病变发生率更高的明确原因尚未确定,但本文提出了一些可能的解释。鉴于人类和大鼠胰腺增生性病变的生物学行为存在差异以及这些病变的拟议形成机制,这一发现与人类风险评估的相关性值得怀疑。